Allocation and group distribution
FEMALE BREAST CANCER
Interested and eligible patients were informed about the procedure, and possible contraindications were explained and clarified by the study director. Participation in the study required a physician’s approval. All participants without contraindications received a declaration of consent. Voluntary consent by signature was required for participation in the study. Furthermore, we intended to allocate our participants to either the intervention or the control group by drawing lots at random.In reality, the following situations occurred:In the beginning of the study, we had nearly enough participants available (Due to corona pandemic, the study had to be terminated prematurely, which explains the small sample size (In the end, a total of 41 female breast cancer patients (age: 56.68 ± 9.87 years; height: 164.93 ± 6.94 cm; weight: 76.61 ± 15.10 kg; BMI: 28.18 ± 5.33) took part in this study. As part of an adjuvant therapy, 51.2% of our participants had received chemotherapy (IG: CONSORT flow diagram